ClinicalTrials.gg
RecruitingNCT04596592PUBERTYUpdated Jun 10, 2025

Pubertal Blockade and Estradiol Effects on Cardiometabolic Health for Transitioning Youth

An observational study in Transgenderism, Gender Dysphoria and Insulin Sensitivity, sponsored by University of Colorado, Denver. Recruiting at 1 site in United States. Open to participants aged 13 Years to 16 Years. Per ClinicalTrials.gov, last updated 2025-06-10.

Primary conditionGender DysphoriaRegistry: TranssexualismReclassifiedWhy we changed it
Registry
Transsexualism — the first condition term the registry derived for this study.
ClinicalTrials.gg
Gender Dysphoria
Why
  1. Transsexualism is a broad heading, used only when no more specific condition is named.
  2. The study's listed conditions name Gender Dysphoria.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of Colorado, Denver · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Feb 2021; still recruiting 5 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
90
Ages
13 Years to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Gender Dysphoria with a site in United States — 11 open to participants now, 13 under way, 3 of them phase 3. Gender Dysphoria · United States.

Planned enrollment
5th of 16
90 · median 46
Started
2021
with 2 others
Observational
16 of 31
5 open now
Primary completion
2026-07
later than 2 of 12 live
Registered
12th of 31
by date
Lead sponsor
3 of 31
University of Colorado, Denver

Among the 31 studies in Gender Dysphoria with a site in United States, this one is the 5th largest by planned enrollment of the 16 observational ones that give a count, is one of 3 that started in 2021, is one of 16 observational ones, reaches primary completion later than 2 of the 12 other live ones, and was the 12th registered.

Gender Dysphoria

85 studies on the registry are indexed under Gender Dysphoria; 38 are open to participants now.

Browse Gender Dysphoria studies →

Open to participants now

11 of the 31 studies in Gender Dysphoria with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 31 Gender Dysphoria studies recruiting now, 15 (48%) set no upper age limit and 10 (32%) stop at 75 or younger; 7 take children under 18; 11 take healthy volunteers.

This study: 13 Years to 16 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Gender Dysphoria with a site in United States, or all of them as a file.
02

Study summary

To evaluate the effect of estradiol with or without a prior gonadotropin releasing hormone analogue on insulin sensitivity and vascular function in transgender females compared to cisgender controls.

03

Conditions studied

  • Transgenderism
  • Gender Dysphoria
  • Insulin Sensitivity

Browse trials for

04

In context

Gender Dysphoria Reclassified

85 studies on the registry are indexed under Gender Dysphoria; 38 are open to participants now.

This study's planned enrollment of 90 is close to the median of 100 across 52 observational studies indexed under Gender Dysphoria.

Browse Gender Dysphoria studies →

Lead sponsor

University of Colorado, Denver is the lead sponsor of 1,547 studies on the registry; 318 are open to participants now.

Of its 148 completed or terminated interventional studies of FDA-regulated products, 93 (63%) have results posted.

Compared within Gender Dysphoria, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Transsexualism. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
13 Years to 16 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Transgender and cisgender adolescents

Eligibility criteria

Inclusion Criteria (transgender females):

  • Identify as a transgender female
  • Age 13-16 years at the time of enrollment
  • If on a gonadotropin releasing hormone analogue, > 6 months exposure
  • Plan to start estradiol clinically in \< 4 months

Inclusion Criteria (cisgender males and females):

  • Males and females ages 13-16 years

Exclusion Criteria:

  • Cognitive, psychiatric, or physical impairment resulting in inability to tolerate the study procedures
  • Antipsychotic medication use
  • Type 1 or 2 diabetes (by medical history)
  • Polycystic ovarian syndrome (PCOS for cisgender females)
  • Hypertension (resting BP ≥ 140/90 mm/Hg)
  • Weight> 400 lbs
  • On oral progesterone medications (including oral progesterone or progestin, combined oral or etonogestrel implant)
  • Pregnancy (for cisgender females)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
90 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Transgender
  • Cisgender
07

What researchers measure

Primary outcomes

  1. Insulin sensitivity

    Time frame: Change from baseline to 12 months

  2. Brachial artery flow mediated dilation

    Time frame: Change from baseline to 12 months

Secondary outcomes

  1. Large artery stiffness

    Carotid artery ultrasound

    Time frame: Change from baseline to 12 months

  2. Cerebrovascular function

    Middle cerebral artery blood flow

    Time frame: Change from baseline to 12 months

  3. VO2 peak

    Time frame: Change from baseline to 12 months

  4. Fat mass

    DXA

    Time frame: Change from baseline to 12 months

  5. Fat-free mass

    DXA

    Time frame: Change from baseline to 12 months

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2021 (actual). Primary completion is estimated for Jul 2026, 65 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2020
First posted
Oct 22, 2020
StartActual
Feb 15, 2021
Primary completionEst.
Jul 31, 2026
CompletionEst.
Jul 31, 2026
Last update
Jun 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04596592
Responsible party
Sponsor
First posted
Oct 22, 2020
Start date
Feb 15, 2021
Primary completion
Jul 31, 2026 (estimated)
Completion
Jul 31, 2026 (estimated)
Last update
Jun 10, 2025

Study contacts

Natalie Nokoff, MD, MSCS
Contact
Natalie.Nokoff@childrenscolorado.org
720-777-3607
Natalie Nokoff, MD, MSCS
principal investigator · University of Colorado, Denver

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion